October 7, 2022 8:39am

Bad news can be good news and good news can be bad news and usually sold into ... as US adds fewest jobs this Year as labor market cools

News: -Alnylam Pharmaceuticals (ALNY +$5.63 or +2.78%) the U.S. FDA approved a label expansion for OXLUMO® (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate (UOx) and plasma oxalate (POx) levels in pediatric and adult patients.

Indications: 4 Negative Indications, 3 Positive Indications, 2 BUYs, with 1 Pump/Promote (BSTG – the usual suspect)

No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes

Why do I keep writing this blog/newsletter to inform investors, what they need to hear that others won’t say or write!

8:45 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are DOWN -0.91% or (-274 points), S&P futures are DOWN -1.26% or (-47 points) and NASDAQ futures are DOWN -1.84% or (-213 points) early in the pre-open – so far,

 

Stock futures were down and mostly weak on Friday morning,

European markets were mixed and mostly retreating,

Asia-Pacific markets fell ahead of U.S. jobs report

 

Henry’omics:

Indexes seesawed and then dropped like a stone on Thursday, as traders weighed sharp swings in stocks and rates to start the month.

The S&P closed down 1% after losses accelerated into the close while the Dow tumbled nearly 350 points, or 1.15%. The Nasdaq fell 0.7%.

Follow-on Information: Shares of Agenus (AGEN) shares jump 18.4% (+0.43) on Thursday. First, the company on Wednesday (+$0.16) said it planned to present data on botensilimab, a therapy that is being studied for its effectiveness as a combination drug or a monotherapy to active T-cell immune responses in patients who have pancreatic cancer, colorectal cancer, or melanoma, a type of skin cancer. Tuesday saw (+$0.12) after Monday’s (+$0.04) following the Previous Friday’s (-$0.01). Another move that helped push up the stock was the announcement of inside buying of Agenus stock by some members of the company's board of directors on Wednesday, including Susan Hirsch, Wadih Jordan, Ulf Wiinberg, and Timothy Wright, totaling more than 30,000 Agenus shares. <Motley Fool> The ONLY company lately that its BOD stepped-up, other should consider!!

Economic Data Docket: Nonfarm payrolls increased 263,000 for the month, compared to the Dow Jones estimate of 275,000. The unemployment rate was 3.5% vs the forecast of 3.7%.

 

RegMed Investors’ (RMi) closing bell: “no, good and bad news makes little difference in sector pricing as electronic trading, algorithms and “hedges” make the trade.” … https://www.regmedinvestors.com/articles/12638

 

Ebb and flow:

Q4 – 3 positive and 1 negative closes

Q3/22 –

·         September – 1 holiday, 10 positive and 11 negative closes

·         August – 1 neutral, 11 positive and 11 negative closes

·         July - 1 holiday, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative Indications:

Beam Therapeutics (BEAM) closed up +$0.39 to $51.34 after Wednesday’s -$0.65, Tuesday’s +$3.71 and Monday’s +$0.25 with a negative -$3.44 or -6.70% pre-open indication,

Sage Therapeutics (SAGE) closed up +$1.29 to $42.66 after Wednesday’s +$0.14, Tuesday’s +$1.64 and Monday’s +$0.43 with a negative -$1.28 or -3% pre-open indication

Verve Therapeutics (VERV) closed up +$0.19 to $36.34 after Wednesday’s +$0.43, Tuesday’s +$2.31 and Monday’s -$0.94 with a negative -$0.83 or -2.28% pre-open indication,

Voyager Therapeutics (VYGR) closed down -$0.14 to $6.17 after Wednesday’s -$0.30, Tuesday’s +$0.98 and Monday’s -$0.29 with a negative -$0.30 or -4.86% pre-open indication,

 

Positive:

Alnylam Pharmaceuticals (ALNY) closed +$1.35 to $202.37 with a positive +$5.63 or +2.78%) pre-open indication,

Intellia Therapeutics (NTLA) closed up +$1.77 after Wednesday’s +$0.04, Tuesday’s +$5.05 and Monday’s -$0.13 with a positive +$0.99 or +1.58%,

uniQure NV (QURE) closed up +$0.10 to $20.21 after Wednesday’s -$0.17 with a positive +$0.35 or +1.73% pre-open indication,

 

Maintaining BUY:

Agenus (AGEN) closed up again +$0.43 to $2.80 after Wednesday’s +$0.16, Tuesday’s +$0.12, Monday’s +$0.04 and last Friday’s -$0.01 with a negative -$0.05 or -1.79% pre-open indication,

Solid Biosciences (SLDB) closed down -$0.0041 to $0.483 after Wednesday’s -$0.022, Tuesday’s +$0.015, Monday’s +$0.0284 and last Friday’s -$0.0016 with a positive +$0.03 or +5.59% pre-open indication after merger/acquisition of AvantiBio and a $75 million Bain financing

 

Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed up +$1.30 with 4,490 shares traded after Wednesday’s -$0.45 with 2,705 shares traded, Tuesday’s -$0.39 with 2,300 shares traded, Monday’s -$0.71 with 2,918 shares traded, Friday’s +$0.10 with 2,083 shares traded and last Thursday closed FLAT with 1,100 shares traded <3-month average = 2,220 shares>,

Questions need to be answered and they NEVER are for shareholders; as the First Amendment of the U.S. Constitution does guarantee the “freedom of speech, or of the press” … but I guess NOT to respond?

  • Who, WHAT and WHERE are pumping and promoting the “spikes” in volume and share price … coming from?
  • What is DST Capital?  Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG?  Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
  • Are Chinese communist bureaucrats from Beijing, China directing the company’s activities with BSTG being their corporate “concubine”?

 

The BOTTOM LINE:  Reiterating, “There is STILL many a concern of sentiment and conviction in the cell and gene therapy sector”.

I STILL believe the sector is headed into “correction” which means that investors should remain cautious.

The final Q4 is HERE … and then back to earnings season!

I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!

As I continually write, “The real question that should be asked is how many companies are at the end of sentiments …  leash?

Start by looking at cell and gene therapy companies trading below cash!” 

When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.

As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.” That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to IDENTIFY the coming “losing” positions.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.